Skip to content

Ulthera System (Ultherapy)

Save device

HIFU/Ultrasound Lifting · Microfocused ultrasound + DeepSEE imaging

Technology: HIFU & Ultrasound

Classification & configurations

Category group: Skin tightening & remodeling (RF microneedling, monopolar RF, HIFU)

Legacy model

At a glance

New-unit reference · older model
$130k–$175kSource not documented
Used asking price
$20k–$60kSource not documented
FDA status
Supplies & recurring costs
See supply and replacement costs below.
View supply details
Sources and verified data on file

Data on file

Recurring consumables
Not verified
Used asking prices
Not verified
  • This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
  • Bottle prices and estimates may still appear under Treatment & running costs.
  • The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.

Figures are reference points, not current offers. Used asking prices are not completed-sale values.

Read FDA-cleared indicationsExact wording from 10 FDA records

DEN080006

1064nm: The Cynosure Affirm Family laser is intended for the coagulation and hemostasis of benign vascular lesions, such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), Caf6 au lait macules, seborrheic keratoses, nevi, chloasma, verrucea, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue/black tattoos) and plaques. The laser is also indicated for the treatment of wrinkles such as, but not limited to, periocular and perioral wrinkles. 1320nm: The Cynosure Affirm Family laser is indicated for use in general surgery and dermatology for the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also indicated for the treatment of periorbital and perioral wrinkles. It is also indicated for the treatment of fine lines and wrinkles. 1440nm: The Cynosure Affirm Family laser is indicated for use in general surgery and dermatology for the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also indicated for the treatment of periorbital and perioral wrinkles and pigmented lesions. The XPL Pulsed Light System Handpiece is intended for permanent hair reduction and the treatment of dermatological vascular lesions, facial and leg veins, benign pigmented lesions, and inflammatory acne. The Affirm Family System Laser Attachment is intended for: Er:YAG 2,940 nm - for skin resurfacing and for the incision, excision, ablation or vaporization of soft bodily tissues.

Verbatim from the FDA De Novo decision summary, retrieved 8 Sep 2026.

K121700 (Ulthera, Inc., 2012)

The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow (current cleared indication) • lift lax submental (beneath the chin) and neck tissue (requested expanded indication)

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K122528 (Ulthera, Inc., 2012)

The Ulthera' System is indicated for use as a non-invasive dermatological aesthetic treatment to: * lift the eyebrow Description of Change: The proposed change is to extend the current six-month shelf life period to a twelve-month shelf life period for the UltheraO System Transducers.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K132028 (Ulthera, Inc., 2013)

The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow (current cleared indication) • lift lax submental (beneath the chin) and neck tissue (cleared indication). The Ulthera System in conjunction with the Ulthera DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin (requested indication) • confirm appropriate depth of treatment such as to avoid bone (requested indication)

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K134032 (Ulthera, Inc., 2014)

The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue • improve lines and wrinkles of the décolleté. The Ulthera System in conjunction with the Ulthera DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K180623 (Ulthera, Inc., 2018)

The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté. The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K233996 (Ulthera, Inc., 2024)

The Ulthera System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • Lift the eyebrow • Lift lax submental (beneath the chin) and neck tissue, which can also affect the appearance of lax tissue in the submental and neck regions • Improve lines and wrinkles of the décolleté. The Ulthera® System, in conjunction with the Ulthera® DeepSEE® transducer, allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • Ensure proper coupling of the transducer to the skin • Confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K243035 (Ulthera, Inc., 2025)

The Ulthera System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • Lift the eyebrow • Lift lax submental (beneath the chin) and neck tissue, which can also affect the appearance of lax tissue in the submental and neck regions • Improve lines and wrinkles of the décolleté • Improve the appearance of skin laxity on the abdomen, anterior arms, and posterior arms. The Ulthera® System, in conjunction with the Ulthera® DeepSEE® transducer, allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • Ensure proper coupling of the transducer to the skin • Confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K250418 (Ulthera, Inc., 2025)

The Ulthera System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté • improve the appearance of skin laxity on the abdomen, anterior arms, and posterior arms. The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K260618 (Ulthera, Inc., 2026)

The Ulthera® System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté • improve the appearance of skin laxity on the abdomen, anterior arms, posterior arms, and knees. The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

Page updated: September 4, 2026 · How we verify

Older-model price references
New-unit reference$130k–$175k
Source not documented
Used$20k–$60k
Source not documented

Axis runs $0–$175k. Reference figures, not current offers. Used asking prices are not completed-sale values.

Consumable cost per treatment

Not verified

We hold no per-treatment consumable price for this device from a dated source. Ask the seller for a written per-treatment cost.

Price sourcesSources, dates and configurations
New-unit reference (older model): $130k–$175k·Researched estimate — no dated source on file yet; not a quote.
Used asking range: $20k–$60k·Researched estimate — no dated source on file yet; not a quote.
Key factsCompany, specifications and verification dates
Key facts
ManufacturerUlthera (Merz)
CompanyOwner: Merz Group (Merz Holding GmbH & Co. KG), founding Merz family (family / founder owned, since 1908) · Distribution: direct
Parent companyMerz Aesthetics
Brand ownerUlthera
Built by (OEM)Ulthera Inc.
CategoryHIFU/Ultrasound Lifting
TechnologyMicrofocused ultrasound + DeepSEE imaging
FDA statusFDA Cleared
510(k) citationDe Novo: DEN080006, K121700, K122528, K132028, K134032, K180623, K233996, K243035, K250418, K260618
New-unit reference (older model)$130k–$175k
Used asking range$20k–$60k
ConsumablesNot published
Launch year2009
PricingNot published
Manufacturer-source documents checkedNot published

Overview

US lift claim marketed for years (FDA status under verification — see our FDA guide); transducers consumable

How it worksTechnology and manufacturing

How the technology works

Microfocused ultrasound with visualization (MFU-V): the transducer images the tissue plane in real time (DeepSEE), then delivers focused thermal coagulation points at precise depths — 4.5mm (SMAS/platysma), 3.0mm (deep dermis), 1.5mm (superficial dermis) — triggering neocollagenesis and gradual lift over 2-6 months.

Marketed with "lift" language for brow, submental, and neck, plus decollete wrinkle improvement (FDA status under verification — see our FDA guide). Results are line-count-dependent; skimped counts are the #1 cause of "Ultherapy didn't work" reviews.

Patented technology

DeepSEE is the real differentiator — transducer ultrasound imaging confirms coupling and target depth before firing, which no blind-delivery HIFU clone offers. "See what you treat" is load-bearing, not just branding.

Origin

Mesa, Arizona, USA (Ulthera, Inc., a Merz Aesthetics company).

FDA & regulatory detailClearance timeline, authorization route and citation notes
Documented clearance timeline
Documented dates: Launch 2009, Clearance 2009, Clearance 2012, Clearance 2014, Clearance 2024, Clearance 2025200920092012201420242025

Launch 2009 · Clearance 2009 · Clearance 2012 · Clearance 2014 · Clearance 2024 · Clearance 2025 · DEN080006; K121700; K122528; K132028; K134032; K180623; K233996; K243035; K250418; K260618

Authorized via 510(k)

De Novo: DEN080006 (decision 11 Sep 2009). 510(k): K121700, K122528, K132028, K134032, K180623, K233996, K243035, K250418 and K260618. Checked 4 Sep 2026.

FDA-cleared indications (verbatim)

DEN080006

1064nm: The Cynosure Affirm Family laser is intended for the coagulation and hemostasis of benign vascular lesions, such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), Caf6 au lait macules, seborrheic keratoses, nevi, chloasma, verrucea, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue/black tattoos) and plaques. The laser is also indicated for the treatment of wrinkles such as, but not limited to, periocular and perioral wrinkles. 1320nm: The Cynosure Affirm Family laser is indicated for use in general surgery and dermatology for the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also indicated for the treatment of periorbital and perioral wrinkles. It is also indicated for the treatment of fine lines and wrinkles. 1440nm: The Cynosure Affirm Family laser is indicated for use in general surgery and dermatology for the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also indicated for the treatment of periorbital and perioral wrinkles and pigmented lesions. The XPL Pulsed Light System Handpiece is intended for permanent hair reduction and the treatment of dermatological vascular lesions, facial and leg veins, benign pigmented lesions, and inflammatory acne. The Affirm Family System Laser Attachment is intended for: Er:YAG 2,940 nm - for skin resurfacing and for the incision, excision, ablation or vaporization of soft bodily tissues.

Verbatim from the FDA De Novo decision summary, retrieved 8 Sep 2026.

K121700 (Ulthera, Inc., 2012)

The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow (current cleared indication) • lift lax submental (beneath the chin) and neck tissue (requested expanded indication)

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K122528 (Ulthera, Inc., 2012)

The Ulthera' System is indicated for use as a non-invasive dermatological aesthetic treatment to: * lift the eyebrow Description of Change: The proposed change is to extend the current six-month shelf life period to a twelve-month shelf life period for the UltheraO System Transducers.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K132028 (Ulthera, Inc., 2013)

The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow (current cleared indication) • lift lax submental (beneath the chin) and neck tissue (cleared indication). The Ulthera System in conjunction with the Ulthera DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin (requested indication) • confirm appropriate depth of treatment such as to avoid bone (requested indication)

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K134032 (Ulthera, Inc., 2014)

The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue • improve lines and wrinkles of the décolleté. The Ulthera System in conjunction with the Ulthera DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K180623 (Ulthera, Inc., 2018)

The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté. The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K233996 (Ulthera, Inc., 2024)

The Ulthera System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera System is indicated for use as a non-invasive dermatological aesthetic treatment to: • Lift the eyebrow • Lift lax submental (beneath the chin) and neck tissue, which can also affect the appearance of lax tissue in the submental and neck regions • Improve lines and wrinkles of the décolleté. The Ulthera® System, in conjunction with the Ulthera® DeepSEE® transducer, allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • Ensure proper coupling of the transducer to the skin • Confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K243035 (Ulthera, Inc., 2025)

The Ulthera System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • Lift the eyebrow • Lift lax submental (beneath the chin) and neck tissue, which can also affect the appearance of lax tissue in the submental and neck regions • Improve lines and wrinkles of the décolleté • Improve the appearance of skin laxity on the abdomen, anterior arms, and posterior arms. The Ulthera® System, in conjunction with the Ulthera® DeepSEE® transducer, allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • Ensure proper coupling of the transducer to the skin • Confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K250418 (Ulthera, Inc., 2025)

The Ulthera System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté • improve the appearance of skin laxity on the abdomen, anterior arms, and posterior arms. The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

K260618 (Ulthera, Inc., 2026)

The Ulthera® System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté • improve the appearance of skin laxity on the abdomen, anterior arms, posterior arms, and knees. The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to visualize the dermal and subdermal layers of tissue to: • ensure proper coupling of the transducer to the skin • confirm appropriate depth of treatment such as to avoid bone

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

Marketed for

HIFU / Ultrasound — Microfocused ultrasound + DeepSEE imaging

Marketing claims are the manufacturer's own and are not the same as a cleared indication.

Parent company: Merz Aesthetics

Legal manufacturer: Ulthera Inc. (United States)

Applicant on the FDA record

Ulthera, Inc.The applicant named on the FDA record can differ from the brand shown on the device.

Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.

Look-alike devices

Comparing an unbranded HIFU (focused ultrasound) unit? Check the exact model rather than relying on similar photos or treatment claims.

Listed manufacturer for this profile: Ulthera Inc.

  • FDA record: Match any claimed 510(k) or De Novo number to the exact model and applicant in the FDA database.
  • Support: Get written warranty, training, consumables and service terms from the seller.
  • Financing: Confirm availability for the exact unit before including it in your budget.

We do not profile these unbranded units or verify their support and financing terms. This profile’s FDA record applies to the named device, not every similar-looking unit.

What we publish about legal and safety matters

Treatment & running costs

Treatments

Sessions & timing

No treatment schedule documented yet.

What practices charge

No sourced treatment price on file.

Supplies & recurring costs

Supply pricing is not documented with a dated source yet. Request an itemized supply quote.

  • Vendor restrictions: card-metered — license cards or dongles gate treatments
·Dealer quote · Updated Aug 30, 2026
Source notes

Transducer listings (Starlight, MNML Aesthetics) with per-treatment figures derived from price and rated treatment life; chip-gated cartridge grouping per Beautrek. 30 Aug 2026 research pass.

Annual service & support

No annual service cost documented yet.

Payback calculatorModel your own volume, labor and service costs

Estimate your payback

Pre-filled from our published Ulthera System (Ultherapy) data where we have it. Estimates appear once the required inputs are available. Review and adjust every pre-filled value before relying on the result.

Start from

No verified per-treatment supply cost is on file. Enter your own allowance. Use $0 only if you have confirmed that it applies to your practice.

Pre-filled from the midpoint of the published new-price range

20 is an illustrative default — change it to your volume.

No sourced per-session price on file — enter what you charge.

Required — enter your cost; missing data does not mean $0.

Provider or tech time for one treatment, fully loaded. Enter 0 if you own-operate.

Annual service contract ÷ 12, if you carry one.

Your estimate

Enter price you charge per treatment, consumable cost per treatment to see contribution and a payback range.

This model ignores financing — if you lease or borrow, add your monthly payment. Estimates from your inputs and our published ranges — not a projection, guarantee or financial advice. How we calculate this.

ComplianceScreening and contraindications on the manufacturer's record

Contraindications & screening

Open lesions or severe cystic acne in the area, implanted electrical devices, caution over metal implants/filler along planned lines, pregnancy, anticoagulation per protocol, and severe-laxity patients who need surgery.

Warranty & serviceWhat to confirm in writing before you buy

Before buying new or used, confirm in writing:

  • Current warranty coverage
  • Included training
  • Service terms

Chains using this device

A chain listing does not establish availability at every location.

No confirmed chain deployments recorded yet.

Owner & operator reviews

Write a review

No owner or operator reviews yet. Be the first →

Current alternatives

Current catalog models to research. Confirm availability and configuration with the supplier.

Jeisys ULTRAcel Zii

HIFU/Ultrasound Lifting

Classys Shurink Universe

HIFU/Ultrasound Lifting

Research comparisons

Includes current and older models.

History6 tracked changes

Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.

  1. September 4, 2026

    FDA status

    UnknownCleared

    Clearance located on openFDA

    Source: Council round 2 audit, verified on openFDA 2026-09-04

  2. September 4, 2026

    FDA status

    UnknownCleared

    Source: Catalog update

  3. September 4, 2026

    FDA source URL

    https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=DEN080006

    Source: Catalog update

  4. September 4, 2026

    510(k) numbers

    K-number set re-verified against openFDA

    Source: Council round 2 audit, verified on openFDA 2026-09-04

  5. September 4, 2026

    FDA K-numbers

    Source: Catalog update

  6. August 1, 2026

    Record created

    Added to The Aesthetic Index — August 2026

    Source: The Aesthetic Index editorial

Cite this data: The Aesthetic Index, "Ulthera System (Ultherapy) — pricing, FDA status and cost to own", aestheticindex.co (accessed September 24, 2026).

Get the full State of Aesthetic Devices 2026 report

A catalog of US-marketed aesthetic and wellness devices — preview it free.

Get the report

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.